Premium
Is chimeric antigen receptor T‐cell therapy really superior to standard of care as second‐line therapy for large B‐cell lymphoma?
Author(s) -
Saiz Luis Carlos,
Leache Leire,
GutiérrezValencia Marta,
Erviti Juan
Publication year - 2023
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.18505
Subject(s) - chimeric antigen receptor , hazard ratio , interim , interim analysis , medicine , lymphoma , oncology , clinical endpoint , randomized controlled trial , subgroup analysis , meta analysis , immunotherapy , confidence interval , cancer , archaeology , history
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom